In the last trading session, 1.08 million shares of the Anavex Life Sciences Corporation (NASDAQ:AVXL) were traded, and its beta was 0.66. Most recently the company’s share price was $3.68, and it changed around -$0.1 or -2.65% from the last close, which brings the market valuation of the company to $302.16M. AVXL currently trades at a discount to its 52-week high of $10.45, offering almost -183.97% off that amount. The share price’s 52-week low was $3.60, which indicates that the current value has risen by an impressive 2.17% since then. We note from Anavex Life Sciences Corporation’s average daily trading volume that its 3-month average coming to 1.28 million.
Anavex Life Sciences Corporation stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended AVXL as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Anavex Life Sciences Corporation is expected to report earnings per share of $Avadel Pharmaceuticals plc for the current quarter.
Anavex Life Sciences Corporation (NASDAQ:AVXL) trade information
Instantly AVXL has showed a red trend with a performance of -2.65% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -60.47% year-to-date, but still down -13.00% over the last five days. On the other hand, Anavex Life Sciences Corporation (NASDAQ:AVXL) is -27.98% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 66.55% from its current value. Analyst projections state that AVXL is forecast to be at a low of $11 and a high of $11.
Anavex Life Sciences Corporation (AVXL) estimates and forecasts
Anavex Life Sciences Corporation share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -34.17 percent over the past six months and at a 5.00% annual growth rate that is well below the industry average of 13.30%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.03%.
AVXL Dividends
Anavex Life Sciences Corporation’s next quarterly earnings report is expected to be released in May.
